Fundació ACE participates in an international study that provides new information about a variant of the BDNF gene, called BDNFVal66Met, associated with Alzheimer's disease and cognitive decline.
The study is focused on the use of neuroimaging to explore the influence of genetics. The results of the research, published in the prestigious journal Molecular Psychiatry, point that this genetic variant is associated with a greater vulnerability of the connection between two areas of the brain, the hippocampus and the frontal region.
The findings conclude that this variant would lead to a greater cognitive deterioration related to Alzheimer's disease.
The study focused on a first phase in the DIAN cohort, a study coordinated by the University of Washington including people carrying a hereditary genetic mutation that causes Alzheimer's. In a second phase, the research also analysed people diagnosed with Alzheimer's disease in asymptomatic phases, included in the DELCODE and FACEHBI studies, projects coordinated by the German Centre for Neurodegenerative Diseases and Fundació ACE, respectively.
The project counted on the collaboration of some of the leading Alzheimer's research centres internationally.
FACEHBI (Fundació ACE Healthy Brain Initiative) is a study led by Fundació ACE and co-funded by Grifols, Life Molecular Imaging, Araclon, Corachan Clinic and Echevarne. The project, started at the end of 2014, aims to study the evolution of 200 people that experience no cognitive decline but noticing that their memory gets worse.
The evidence shows that make research in these initial phases of Alzheimer’s could be key to developing drugs for treating the disease.